BACKGROUND & AIMS: Liver cT1 , liver T1 , transient elastography (TE) and blood-based biomarkers have independently been shown to predict clinical outcomes but have not been directly compared in a single cohort of patients. Our aim was to compare these tests' prognostic value in a cohort of patients with compensated chronic liver disease. METHODS: Patients with unselected compensated liver disease aetiologies had baseline assessments and were followed up for development of clinical outcomes, blinded to the imaging results. The prognostic value of noninvasive liver tests at pre-specified thresholds was assessed for a combined clinical endpoint comprising ascites, variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma, liver transplantation and mortality. RESULTS: One hundred and ninety-seven patients (61% male) with median age of 54 years were followed up for 693 patient-years (median (IQR) 43 (26-58) months). The main diagnoses were NAFLD (41%), viral hepatitis (VH, 25%) and alcohol-related liver disease (ArLD; 14%). During follow-up 14 new clinical events, and 11 deaths occured. Clinical outcomes were predicted by liver cT1 >825ms with HR 9.9 (95% CI: 1.29-76.4, p=0.007), TE>8kPa with HR 7.8 (95% CI: 0.97-62.3, p=0.02) and FIB-4>1.45 with HR 4.09 (95% CI: 0.90-18.4, p=0.05). In analysis taking into account technical failure and unreliability, liver cT1 >825 ms could predict clinical outcomes (p=0.03), but TE>8kPa could not (p=0.4). CONCLUSIONS: We provide further evidence that liver cT1 , TE and serum-based biomarkers can predict clinical outcomes, but when taking into account technical failure/unreliability, TE cutoffs perform worse than those of cT1 and blood biomarkers.
1H-MRS, Liver MultiScan, T1 mapping, T2* mapping, iron corrected T1